US FDA Office Of New Drugs Likely To Be Headed By Deputy Director Stein
Peter Stein is a familiar face within OND and has been working alongside CDER Director Janet Woodcock on the proposed “modernization” of OND. As a previous recruit from outside FDA, Stein has had time to make the key connections and adjustments to working inside government.
You may also be interested in...
An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."
Amid concerns Office of New Drugs reorganization will result in sponsors receiving conflicting advice, new director offers several items already contemplated to prevent such problems.
US FDA's drug center has been hiring more employees than it has lost over the last few months and hopes the Office of New Drugs reorganization will help retention.